Lymphoma classification update: B-cell non-Hodgkin lymphomas.
Jiang M, Bennani NN, Feldman AL.
Expert Rev Hematol. 2017 May;10(5):405-415. doi: 10.1080/17474086.2017.1318053. Epub 2017 Apr 24.
Resected Diffuse Large B Cell Lymphoma: Does Extirpation Mean No Irradiation in the PET-Response Based Milieu?
McMullen KP, Sawyer J.
Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):716-717. doi: 10.1016/j.ijrobp.2024.01.207.
@doctordoescancer.
Said H.
CMAJ. 2020 Aug 4;192(31):E895-E897. doi: 10.1503/cmaj.200261.
Primary Cutaneous B-cell Lymphomas.
Hope CB, Pincus LB.
Clin Lab Med. 2017 Sep;37(3):547-574. doi: 10.1016/j.cll.2017.05.009.
Intravascular large B-cell lymphoma: the heterogeneous clinical manifestations of its classical and hemophagocytosis-related forms.
Nakamura S, Murase T, Kinoshita T.
Haematologica. 2007 Apr;92(4):434-6. doi: 10.3324/haematol.11372.
Mediastinal large B-cell lymphoma vs classic Hodgkin lymphoma.
Chadburn A, Frizzera G.
Am J Clin Pathol. 1999 Aug;112(2):155-8. doi: 10.1093/ajcp/112.2.155.
Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO, Mehta A.
Expert Rev Hematol. 2016 May;9(5):471-7. doi: 10.1586/17474086.2016.1146584. Epub 2016 Feb 19.
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Abramson JS.
Oncologist. 2006 Apr;11(4):384-92. doi: 10.1634/theoncologist.11-4-384.
[Treatment of indolent cutaneous B-cell lymphoma].
Wobser M.
Hautarzt. 2017 Sep;68(9):721-726. doi: 10.1007/s00105-017-4022-4.
Primary mediastinal large B-cell lymphoma.
Savage KJ.
Oncologist. 2006 May;11(5):488-95. doi: 10.1634/theoncologist.11-5-488.
